Scilex Holding Co (SCLX): Total Liabilities
$576.73M
As of 2025-12-31
$564.05M
As of 2026-06-30
+125.5%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $576.73M | +101.9% | 2026-04-10, Balance as of period end |
| 2024-12-31 | $285.59M | +4.1% | 2026-04-10, Balance as of period end |
| 2023-12-31 | $274.25M | +445.4% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $50.29M | -83.3% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $301.81M | n/m | 2023-03-07, Balance as of period end |
| 2020-12-31 | $180.8K | n/a | 2022-02-24, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Scilex Holding Co (SCLX) | 2025-12-31 | $576.73M | +101.9% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $62.17M | -22.3% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $104.17M | -16.2% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $102.49M | -23.3% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $62.51M | -30.3% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $163.15M | +14.6% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $74.01M | -6.2% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $56.20M | -39.8% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $159.25M | -23.2% |
Compare SCLX, DTIL, XFOR, CCCC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗